Opzelura

Generic name: ruxolitinib

Used for: Eczema (atopic dermatitis) · Vitiligo (patches of skin that lose their color) · 1 more

How do you pay?

How to pay the least

Ask for the cash price

Opzelura

No generic is sold yet.

  1. Ask your pharmacy for Opzelura’s cash price, and one or two other pharmacies too.
  2. Opzelura’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameOpzelura
Authorized genericruxolitinib
Regular genericruxolitinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Opzelura?
The original
–
–

Brand nameThe maker’s card

OPZELURA Copay Savings Program

Savings card from Incyte

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a tube

Sign up on opzelura.com 

Or text SAVE to 91830, or call 1-833-613-2333. See the offer on opzelura.com

In the maker’s words

“By using this copay savings card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for OPZELURA may pay as little as $0 per tube.”

From the maker’s offer on opzelura.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Opzelura itself, from the same company, sold without the brand name, and usually for less. For now Opzelura is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OPZELURA is a Janus kinase (JAK) inhibitor indicated for:

  • the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Limitations of Use

Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.

Source: the FDA label for Opzelura (Incyte Corporation), June 30, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/opzelura/